Zepbound vs Ozempic: Long-Term Durability of Response

What "Durability of Response" Actually Means in GLP-1 Therapy

Durability refers to how well a drug sustains its clinical effect over time, not just at a single endpoint. For GLP-1 receptor agonists, clinicians track two distinct durability questions: how long the weight-loss trajectory continues before plateauing, and what happens to weight and glycemia after the drug is stopped.

These are separate problems. A drug can produce a large initial loss but plateau early, or produce a moderate loss that holds steadily for years. The data suggest tirzepatide does better on the first question; both drugs struggle similarly on the second.

Why Mechanism Shapes Durability

Semaglutide acts exclusively on the GLP-1 receptor, reducing appetite and slowing gastric emptying. Tirzepatide adds a second receptor arm: the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP co-agonism appears to amplify the anorectic signal and may reduce GLP-1 receptor desensitization, which is one proposed reason tirzepatide's weight-loss curve continues falling longer than semaglutide's before leveling off. The mechanistic rationale for this is reviewed in detail by Frias et al. In the Journal of Clinical Endocrinology and Metabolism [1].

Plateau Timing: A Key Clinical Difference

In SURMOUNT-1 (N=2,539, 72 weeks), participants on tirzepatide 15 mg had not fully plateaued by the final visit, with body weight still declining at week 60 to 72 [2]. Semaglutide 2.4 mg (Wegovy, not Ozempic) data from STEP-1 (N=1,961, 68 weeks) showed a plateau emerging closer to weeks 48 to 52 [3]. Ozempic's approved diabetes doses plateau earlier still, given that 1 mg semaglutide is a lower exposure than 2.4 mg.

For patients seeking long-term durability, a later plateau means the drug continues working longer before a dose adjustment or switch is needed.

SURMOUNT-1 vs SUSTAIN-7: What the Trial Data Show

These two trials are the primary evidence bases for comparing tirzepatide and semaglutide durability, though a direct head-to-head RCT of Zepbound vs Ozempic at matched doses in the same population has not been published as of mid-2025.

SURMOUNT-1 (Tirzepatide, N=2,539, 72 Weeks)

SURMOUNT-1 enrolled adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity, but without type 2 diabetes. At 72 weeks, mean weight reductions were 15.0%, 19.5%, and 20.9% for the 5 mg, 10 mg, and 15 mg doses, respectively, vs. 3.1% for placebo (P<0.001 for all active doses) [2]. Roughly 57% of participants on 15 mg lost at least 20% of body weight, a threshold rarely reached with any single pharmacologic agent. The trial was published in the New England Journal of Medicine in 2022.

SUSTAIN-7 (Semaglutide vs Dulaglutide, N=1,201, 40 Weeks)

SUSTAIN-7 compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 0.75 mg and 1.5 mg in type 2 diabetes. It is the most methodologically relevant published trial for understanding semaglutide's metabolic durability at Ozempic-range doses [4]. At 40 weeks, semaglutide 1.0 mg reduced HbA1c by 1.73 percentage points and body weight by 6.2 kg from baseline. Semaglutide 0.5 mg reduced weight by 4.5 kg. These are meaningful results, but the magnitude and duration are substantially smaller than what SURMOUNT-1 shows for tirzepatide.

Comparing Across Trials: What the Numbers Can and Cannot Tell You

Cross-trial comparisons have real limits. SURMOUNT-1 enrolled non-diabetic patients; SUSTAIN-7 enrolled people with type 2 diabetes. Baseline weight, concomitant medications, and trial duration differ. An indirect meta-analysis published by Shi et al. (2022) in BMJ found that tirzepatide 15 mg was associated with significantly greater HbA1c reduction and weight loss than semaglutide 1 mg when compared through a network of trials, but the authors noted the absence of a direct RCT as a key limitation [5].

The honest clinical takeaway: the data consistently favor tirzepatide for magnitude and duration of effect, though the comparison is not perfectly controlled.

Long-Term Weight Maintenance: What Happens If You Stop

Both drugs produce substantial regain when stopped. This is the most important durability finding for patients to understand before starting therapy.

The SURMOUNT-4 Discontinuation Data

SURMOUNT-4 enrolled participants who had completed 36 weeks of tirzepatide 10 mg or 15 mg and then randomized them to continue the drug or switch to placebo for an additional 52 weeks. Those who continued tirzepatide lost a further 6.7% of body weight. Those switched to placebo regained a mean of 14.8 percentage points of the weight they had lost, recovering roughly two-thirds of their prior loss within the observation window [6]. The study was published in JAMA in 2024.

Semaglutide Discontinuation: STEP-4 Evidence

The STEP-4 trial used semaglutide 2.4 mg (Wegovy), not Ozempic, but the biology is instructive for any GLP-1 agent. Participants who had lost weight on semaglutide for 20 weeks and then stopped regained a mean of 6.9% body weight over the following 48 weeks, compared to a continued 7.9% loss in those who stayed on the drug [7]. The regain began within the first 12 weeks of discontinuation. There is no published equivalent discontinuation trial for Ozempic specifically, but the pattern is expected to follow the same pharmacologic logic.

Clinical Implication: Both Drugs Require Indefinite Use for Sustained Effect

The American Diabetes Association 2024 Standards of Care describe obesity as "a chronic, relapsing disease requiring long-term treatment" and explicitly state that discontinuation of pharmacotherapy typically leads to weight regain [8]. This framing applies to both tirzepatide and semaglutide. Patients and clinicians should plan for indefinite therapy at the lowest effective dose rather than treating these agents as finite courses.

Glycemic Durability in Type 2 Diabetes

For patients using Ozempic specifically for type 2 diabetes, glycemic durability is often the primary outcome rather than weight. Tirzepatide is also approved for T2D as Mounjaro.

HbA1c Trajectories Over Time

In the SURPASS-2 trial (N=1,879, 40 weeks), tirzepatide 15 mg reduced HbA1c by 2.34 percentage points from a baseline of 8.28%, compared to 1.86 percentage points for semaglutide 1 mg (P<0.001) [9]. More participants on tirzepatide 15 mg reached HbA1c <5.7% (a near-normoglycemic threshold) than on semaglutide: 27% vs. 6%, respectively. SURPASS-2 is the only completed direct head-to-head trial comparing tirzepatide and semaglutide in T2D, though it used semaglutide at the Ozempic dose, not the higher Wegovy dose.

Beta-Cell Function Preservation

A secondary analysis of SURPASS trials found that tirzepatide produced greater improvements in HOMA-B (a surrogate for beta-cell function) than semaglutide, suggesting the drug may slow the progressive beta-cell decline that characterizes T2D over time [10]. Whether this translates to fewer insulin initiations or reduced cardiovascular events over a decade is not yet established from completed outcome trials.

Cardiovascular Outcomes

Semaglutide has an established cardiovascular outcomes trial: SUSTAIN-6 (N=3,297, 104 weeks) demonstrated a 26% relative risk reduction in the primary MACE endpoint vs. Placebo [11]. Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT (SURMOUNT-MMO), is ongoing as of mid-2025. For patients with established cardiovascular disease, semaglutide's Ozempic currently has a stronger outcomes evidence base. This is a genuine durability advantage for Ozempic in that specific population.

Real-World Durability: Persistence, Adherence, and Cost

Clinical trials tell you what a drug can do under controlled conditions. Real-world durability depends on whether patients stay on the drug at all.

Persistence Rates

A 2023 analysis of U.S. Pharmacy claims data found that 12-month persistence on semaglutide (any formulation) for weight management was approximately 44% [12]. Comparable data for tirzepatide is limited by its more recent launch, but early analyses suggest similar attrition patterns driven by cost and side effects rather than efficacy failure.

Tolerability and Dose Escalation

Both drugs require slow dose escalation to minimize nausea and vomiting. Tirzepatide's starting dose is 2.5 mg weekly, escalated by 2.5 mg every 4 weeks to a target of 5 to 15 mg. Semaglutide (Ozempic) starts at 0.25 mg for 4 weeks, then 0.5 mg, with optional titration to 1 mg or 2 mg. Gastrointestinal adverse events are the leading cause of discontinuation in both trials and real-world practice. SURMOUNT-1 reported nausea in 33.7% of tirzepatide 15 mg participants vs. 16.2% with placebo [2].

Cost and Insurance Coverage

Ozempic carries list prices near $900 per month; Zepbound's list price is approximately $1,060 per month as of early 2025. Insurance coverage for Ozempic in diabetes is substantially broader than Zepbound's coverage for obesity, which varies widely by plan. The practical durability of either drug is zero if a patient cannot afford continuous access.

Should You Switch from Zepbound to Ozempic?

This is one of the most common clinical questions at HealthRX. The short answer: switching from tirzepatide to semaglutide is generally not recommended for efficacy reasons, but may be necessary for formulary, insurance, or tolerability reasons.

When Switching Makes Clinical Sense

A switch from Zepbound to Ozempic may be appropriate in four scenarios: (1) insurance coverage changes and only Ozempic is covered, (2) the patient has established cardiovascular disease where SUSTAIN-6 data support semaglutide specifically, (3) tirzepatide side effects are intolerable but the patient tolerates semaglutide at a lower dose, or (4) the patient is transitioning from obesity treatment back to a T2D-primary treatment goal where Ozempic's labeling aligns better.

What to Expect When Switching

Switching from tirzepatide to semaglutide typically produces some weight regain. Because tirzepatide's dual-agonist mechanism delivers a stronger anorectic signal than semaglutide alone, patients often notice increased appetite within weeks of switching, even before any scale change. Clinicians should counsel patients that some weight regain (estimated 5 to 10% of prior loss based on the mechanism difference and SURPASS-2 effect-size gap) may occur over 3 to 6 months following the switch.

There is no published RCT specifically studying the Zepbound-to-Ozempic switch sequence. This framework is based on pharmacokinetic half-life data (tirzepatide half-life approximately 5 days, semaglutide approximately 7 days) and the effect-size differences seen in SURPASS-2 [9].

Dosing Continuity During a Switch

When switching, the last tirzepatide dose should be taken as scheduled, with semaglutide initiated the following week at the standard starting dose (0.25 mg), then titrated up. There is no established wash-out period needed given both drugs' weekly dosing and similar half-lives. The FDA label for neither drug specifies a required interval for switching between GLP-1 agents.

When Not to Switch

If a patient is tolerating Zepbound, achieving weight loss, and has stable formulary access, switching to Ozempic will reduce efficacy without adding a known clinical benefit. The SURPASS-2 data show a statistically and clinically significant advantage for tirzepatide in both weight and HbA1c outcomes [9].

Comparing Durability: A Summary Decision Framework

The table below distills the key durability variables for a clinician choosing between or switching between these agents.

| Variable | Zepbound (Tirzepatide) | Ozempic (Semaglutide) | |---|---|---| | Max approved weekly dose | 15 mg | 2.0 mg (T2D); 2.4 mg for obesity as Wegovy | | Mean weight loss at max dose | 20.9% at 72 wk (SURMOUNT-1) | ~6.2 kg at 40 wk in T2D (SUSTAIN-7) | | HbA1c reduction vs semaglutide 1 mg | 2.34% vs 1.86% (SURPASS-2) | Reference | | Weight regain at 52 wk post-stop | 14.8 pp of prior loss (SURMOUNT-4) | ~6.9% body weight over 48 wk (STEP-4, Wegovy) | | Cardiovascular outcomes RCT | Ongoing (SURPASS-CVOT) | Completed; 26% MACE reduction (SUSTAIN-6) | | Plateau timing | Delayed beyond 60 weeks | Approximately 48 to 52 weeks | | Mechanism | GIP + GLP-1 dual agonist | GLP-1 selective agonist |

The data across trials and one completed head-to-head (SURPASS-2) consistently show tirzepatide outperforming semaglutide on weight and glycemia at equivalent durations. Ozempic retains a specific advantage in patients where the SUSTAIN-6 cardiovascular evidence is directly relevant. At the current state of the evidence, a patient who can access and tolerate tirzepatide and whose primary goal is maximum durable weight loss will generally achieve better results staying on Zepbound than switching to Ozempic.

Clinicians prescribing for long-term durability should set clear reassessment intervals: weight at 12 weeks to confirm at least 5% loss (the threshold below which the ADA recommends reconsidering pharmacotherapy [8]), and HbA1c at 3 and 6 months in T2D patients to confirm adequate glycemic response.